Cardiomyopathies constitute a huge burden to both communities and health systems in Africa. Together with rheumatic heart disease, tuberculous pericarditis, systemic hypertension and its complications, cardiomyopathies are the major causes of heart disease in black African populations, causing great morbidity and mortality in young and economically active people (6, 7) and being responsible for more than 20% of all admissions for cardiovascular diseases in both children and adults.
INTRODUCTION
Cardiomyopathies are forms of disease in which the heart muscle is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension, valve disease and congenital heart disease suffi cient to explain the observed myocardial abnormality. (1) The diseases of the heart muscle constitute the greatest challenge of all the cardiovascular diseases in Africa (2) where, in addition to the cardiomyopathies usually seen in the developed world, there is a high prevalence of specifi c forms of myocardial disease which cause considerable morbid-mortality and affect large numbers of people, but have not been the subject of enough attention from the medical and research communities. They are part of the forgotten or neglected cardiovascular diseases.
The most stricking example of neglected cardiomyopathy is Endomyocardial Fibrosis (EMF). (3) Despite being the most common form of restrictive cardiomyopathy worldwide, affecting an estimated 12 million people, (4) EMF has received little attention from the scientifi c community as shown by the declining number of publications on the subject in the last decades. occurs for reasons that are unclear (5) and within country regional variation has also been reported in Mozambique, (11) Uganda (12) and Nigeria. (13) Several studies in African countries revealed an incidence of Peripartum Cardiomyopathy (PPCM) varying from 1:500 to 1:1000 deliveries. (14, 15, 16) This cardiomyopathy is known to have high incidence and prevalence in the black race, (17, 18, 19) and studies in the USA have shown that African-American women had 2.9-fold more cases of PPCM when compared with whites and 7-fold more cases than Hispanic women. (20) A new challenge for African countries is the HIV-related cardiomyopathy, which constitutes the most important cardiovascular manifestation of HIV infection with a prevalence varying from 10% to 30% in echocardiography or autopsy studies. (21, 22, 23) Its incidence increases with the progression of AIDS (22, 23, 24, 25) and is likely to become even more prevalent as HIV-infected patients live longer. Rapid progression to death in less than 3 months has been reported in patients without antiretroviral therapy (26) either due to HIV-myocarditis or to opportunistic infections, autoimmune response to viral infection, and nutritional defi ciencies. (25, 26, 27, 28) Dilated cardiomyopathy is now the leading cause of heart disease in acutely ill hospitalised patients with HIV in Africa, (29, 30) particularly in those not receiving highly active antiretroviral therapy. (31) The advent of highly active antiretroviral therapy has had an impressive impact on mortality and disease progression in developed countries, but these effects are not yet seen in Africa due to lack of universal access to therapy. Similarly to other parts of the globe, some antiretroviral drugs have several side effects that can lead to cardiac dysfunction. (32) Although important due to the high number of people at risk in Africa, we will not discuss HIV-related cardiomyopathy in detail.
Instead we will concentrate in reviewing the current knowledge on Endomyocardial Fibrosis and Peripartum Cardiomyopathy.
ENDOMYOCARDIAL FIBROSIS

Defi nition
Endomyocardial Fibrosis (EMF) is an extremely debilitating disease, classifi ed as a restrictive cardiomyopathy that is characterised by endocardial fi brous thickening, affecting predominantly the ventricular wall and the atrioventricular valves, which results in ventricular cavity reduction with abnormal diastolic fi lling, and severe tricuspid or mitral regurgitation.
Etiology and determinants
The etiology of EMF remains unknown although several factors have been implicated in its origin. Ethnicity, poverty, malnutrition, dietary factors, infections (viral and parasitic), autoimmunity, allergy (eosinophilia), toxic agents (cerium, cassava, serotonin, plant toxins and vitamin D) and heredity have all been implicated.
The major determinants of EMF seem to be age, gender, ethnic group, social deprivation and eosinophilia. (12, 33, 34, 35) This condition affects predominantly children with more than half the cases being diagnosed during the fi rst decade of life. (36) However, it can occur in infants (37) and a second peak incidence occurs in women of childbearing age.
Childhood EMF affects both sexes. (38) Female preponderance has been found in young adults from Uganda (39) while in Mozambique males are more affected. (33) Regarding ethnics, studies from Uganda reported preponderance of the condition in patients from Rwanda and Burundi that immigrate to the Southwest. (12, 40) In Mozambique, an analysis of referrals to a tertiary unit showed a striking high attack rate in an ethnic group from a rural coastal area in the south of the country, (11) for reasons that could not be determined.
Familial cases of EMF have been described in both clinical (41, 42) and epidemiological studies. (33) The most important conditioning factors seem to be environmental. (9, 43) However, preliminary results of studies performed in Mozambican patients with EMF showed evidence of immunogenetic heterogeneity (Mocumbi, unpublished data).
The role of infectious agents has been mainly supported by fi ndings of sporadic cases of EMF in foreign people from temperate areas after short stays in endemic regions, (44, 45) but it also appears plausible in view of climatic restrictions of the disease.
Plasmodium species, (46) Schistosoma, (47) Microfi laria, (48) Helminths, (35) Coxsackie B virus, (49) Arboviruses and Toxoplasma gondii (49) 
Pathophysiology
Endomyocardial fi brosis appears to start as a febrile episode triggered by an unknown factor followed by ventricular thrombosis which can be associated with facial swelling, body itching, hypereosinophilia and thromboembolism. (52, 35) It is thought that mural and valvar thrombosis evolves to organisation of the thrombus and endocardial fi brosis, affecting mainly the ventricular apices and the recess behind the posterior leafl et of the mitral valve. (39) Mural endocardial fi brosis reduces ventricular cavity size and impedes adequate fi lling leading to restrictive physiology, while fi brosis of the endocardium affecting the papillary muscles, chordae and/or leafl ets causes valve distortion, resulting in severe atrioventricular regurgitation. These two abnormalities are responsible for the typical aspect of small ventricles with severely dilated atria found in this entity.
The sustained low cardiac output results in fi nger and toe clubbing, growth retardation, testicular atrophy, failure to develop male secondary sexual characters and cachexia. (53, 54, 55, 56) In right ventricular EMF, the most common form of presentation either in isolation or as part of biventricular disease, chronic systemic venous hypertension leads to exophthalmos, elevated jugular pressure, gross hepatomegaly and congestive splenomegaly. (56) However, some distinctive features of EMF cannot be explained solely by low cardiac output and retrograde congestion. For instance, there is still some controversy regarding the pathophysiology of the central cyanosis and the voluminous ascites that can lead to ventral or inguinal hernia in the absence of pedal oedema.
(57)
Diagnosis
The clinical picture of EMF depends on the ventricle affected, the duration of disease and the presence of active disease. By the time of clinical presentation patients with EMF are usually at an advanced stage (36) and most give poor clinical history. Interestingly, patients can be mildly symptomatic while having severe structural abnormalities detected on echocardiography. (58, 59) Patients with right-sided EMF often present with exophtalmus, jaundice, peripheral cyanosis, fi nger clubbing, atrial fi brillation, ascitis without pedal oedema, third sound and absence of cardiac murmurs due to free tricuspid regurgitation. (36) In left-sided EMF there is usually a systolic murmur that is typically soft, short and confi ned to early systole, associated with a delayed opening snap, and a loud pulmonary component of the second sound, indicating increased pulmonary pressures. (60) The biological profi le of EMF patients is unspecifi c. Hypereosinophilia is a common fi nding (61) without any evidence of infection or parasitism. (62) The effusions, particularly the ascitic fl uid, are typically exudates having more leukocytes (predominantly lymphocytes) and higher protein content than expected in right heart failure. (63) The electrocardiogram shows no constant pattern. There are usually low voltage QRS complexes, non-specifi c ST-T wave changes, conduction disturbances and atrial arrhythmias in advanced disease. (61) A tall and broad right atrial wave, "qr" pattern in the leads V3R or V1, and delayed right ventricular conduction are characteristic of right EMF. (56, 57) The chest x-ray in right ventricular EMF shows severe right atrial enlargement, a bulge over the left heart border due to dilatation of the infundibulum, and hypoperfused lungs, while in left-sided EMF there is prominent main pulmonary artery, exaggeration of the blood vessels in the lung fi elds and left atrial enlargement. Table 1 .
Computed tomography is seldom used in clinical practice since it adds little to the echocardiography. The presence of a linear calcifi cation distal to the pericardium, along the inner border of the myocardium suggests EMF at conventional and spiral computed tomography. (64) Magnetic Resonance Imaging (MRI) confi rms the O existence of thrombus or calcifi cations, allows an exact delineation of hypoperfused areas that correspond to fi brosis (65) and provides functional information, (65, 66) but is not readily available in most endemic areas. 
Differential diagnosis
In Africa it is important to differentiate left EMF from mitral valve disease due to rheumatic heart disease. The large atria associated with small ventricles characteristic of bilateral EMF allow easy differentiation from dilated cardiomyopathy. Finally, tuberculous and constrictive pericarditis must also be considered, as well as neoplastic infi ltration by lymphomas, particularly in children and young adults.
Management
Although no specifi c therapy for EMF is available, amelioration of acute disease, heart failure and arrhythmias, can be achieved with corticosteroids, diuretics, vasodilators, digitalis, B-blockers and anticoagulants. The overall results of medical therapy have been improving lately but patients with advanced disease need large doses of drugs and frequent admissions to hospital for invasive procedures to alleviate effusions (pericardial, pleural and peritoneal) and control arrhythmias.
Surgery is indicated in patients in NYHA class III and IV since it increases survival and quality of life when compared to medical therapy. (69) It should be performed before irreversible cardiac and hepatic damage occurs. (70) In Africa due to the lack of human and material resources for open-heart surgery in most endemic areas, the surgical experience has been growing slowly. A translational research project including surgical treatment is underway in Mozambique. 
Epidemiology
There are no large population studies on the incidence and prognosis of PPCM in Africa. Hospital-based studies report an incidence of 1:1 000 deliveries in South Africa (15) and 1:500 (73) showing that the incidence is higher than that reported in other parts of the world. (15, 19, 20, 74, 75) Although the highest incidence of PPCM has been reported in women > 30 years of age, (76) it can occur at any age and is frequently seen in young women in Africa and after their fi rst pregnancy.
Etiology and pathogenesis
The etiology of PPCM remains unknown but viral, autoimmune and idiopathic myocarditis are highly suggested. (19) Several hypotheses have been put forward namely myocarditis, viral infection, autoimmune factors, infl ammatory cytokines, abnormal hemodynamic response to physiological changes in pregnancy, prolonged tocolysis and selenium defi ciency. (76, 77, 78, 79, 80) There are discrepancies in the incidence of myocarditis in PPCM that may be due to differences in timing of the myocardial biopsy. (81) While an incidence of myocarditis of about 78% has been reported in newly diagnosed PPCM patients, (81) failure to demonstrate the presence of myocarditis is also common. (82) There is also some evidence that infl ammation -possibly related to autoimmunity -may play a role in the pathogenesis in early stages of the disease process. (83) More recently a study at a single tertiary level hospital in South Africa showed raised levels of infl ammation markers as evidence for a role of apoptosis in PPCM patients. (84) The major risk factors reported for PPCM are black race, advanced maternal age, multiple gestations, twin pregnancy, gestational hypertension and long-term tocolysis. (18, 19, 80) Although the pathophysiology remains largely unknown, a specifi c mechanism has emerged with the recent discovery of an oxidative stress-cathepsin D-16-KDA prolactin cascade in experimental and human PPCM. and tricuspid regurgitation, and a small pericardial effusion. (86) Elevated pulmonary artery pressure and pulmonary arterial hypertension are also seen in the majority of cases. (86) Ventricular thrombosis is common ( Figure 3 ) and has been reported in up to 53% of patients with peripartum cardiomyopathy. (76, 87) Recent thrombi are more shaggy and irregular in confi guration, whereas organised thrombi are more circumscribed and immobile. (88) Some evidence exists for the usefulness of MRI for diagnosis, pathogenic and prognostic consideration in patients with PPCM. (89) Cardiac catheterisation can be used for evaluation of left ventricular function, obtaining endomyocardial biopsies and performing coronary angiography, but is not essential to diagnosis in most cases.
Diagnosis
The 
Differential diagnosis
Peripartum cardiomyopathy presenting as congestive heart failure affecting African women in late pregnancy or in the early puerperium, must be differentiated from dilated cardiomyopathy, endomyocardial fi brosis and HIV-related cardiomyopathy, which are also very common. Similarly, other secondary forms of cardiomyopathy must be ruled out, namely pre-eclampsia, infections, anemia, thiamine defi ciency and alcoholism.
In women with post-natal pre-cordial pain, in which situation the differentiation can present a diagnostic dilemma, (90) symptoms of exercise-related chest pain, exertional dyspnea, and orthopnea point to a primary cardiac pathology, and the clinical signs of pulmonary oedema and gallop rhythm usually exclude a thromboembolic cause.
Complications
The main complications of PPCM are thromboembolism, arrhythmias, organ failure, and obstetric and perinatal complications.
Systemic and pulmonary thromboembolism, described in a considerable number of patients with left ventricular dysfunction, is thought to be due to hypercoagulability and risk of thrombosis during pregnancy and postpartum period, including activation of coagulation factors, increase in plasma fi brinogen, and platelet adhesion. The risk of thrombosis is aggravated by the need for prolonged rest due to congestive heart failure.
Arrhythmias found in women with PPCM include sinus tachycardia, atrial and ventricular tachycardia, atrial and ventricular premature beats. Ventricular arrhythmia is thought to be the cause of sudden death reported in PPCM.
Organ failure is caused by passive congestion associated with hypoperfusion due to cardiac failure and low cardiac output.
Perinatal complications include premature delivery, small for date and low birth weight babies, intrauterine growth retardation and fetal deaths (91, 92) and higher infant mortality.
Management
A multidisciplinary approach involving an obstetrician, cardiologist, anesthesiologist and perinatologist may be required to provide optimal care to PPCM patients. (78, 84, 87) The current management of this condition consists of medical therapy using inotropic support, diuretics, beta-blockers, vasodilators (angiotensinconverting enzyme inhibitors, nitrates or hydralazine) and anticoagulants. Although there is currently no consensus as to whether patients with depressed left ventricular function and sinus rhythm should be anticoagulated to prevent thrombus formation, PPCM presents a higher risk and might need aggressive and pre-emptive coagulation once the diagnosis is made. (93) The role of immunosupression has not been clearly defi ned, but seems to have a place in myocarditis-positive PPCM patients. (94) Immunomodulation using pentoxifylline has been used due to its capacity to reduce production of TNFα, CRP and Fas/Apo-1 (a marker of apoptosis), but further studies are needed to clarify its effects. (95, 96) More recently, the use of bromocryptine (inhibitor of prolactine) was successful in preventing left ventricular dysfunction in subsequent pregnancies of women known to have had PPCM. (97) Effective medical treatment reduces mortality rates and increases the number of women who fully recover left ventricular systolic function. (20, 84) However, the adverse effects of medical therapy on the fetus or breast-feeding infant must be borne in mind. While hyponatremia has been reported in infants born from mothers taking diuretics prepartum, angiotensin-converting enzyme inhibitors are absolutely contraindicated prepartum, when they may be associated with adverse fetal renal effects and an increase in neonatal mortality. (90) Beta-blockers are generally safe in pregnancy. (95) Surgical management with cardiac transplantation is indicated in severe cases with progression of left ventricular dysfunction despite medical therapy. Mechanical ventricular assistance can be used as a bridge to transplantation.
Outcome
The course and outcome of this cardiomyopathy are largely unpredictable. Maternal mortality, initially reported to reach 85%, (76) has now decreased to 9%-50%. (17, 84, 91, 99, 100) About half patients with PPCM recover, (19, 84, 99) while 25% evolve to death within 3 months due to heart failure, arrhythmias or thromboembolism, and the remaining patients develop dilated cardiomyopathy ( Figure 3 ). The overall prognosis has been improved with increase in the percentage of women who recover left ventricular function and reduction of mortality, due to advances in the therapeutics of heart failure in recent years, mainly the arrival of new drugs to treat heart failure, the benefi ts of cardiac transplantation and the use of mechanical ventricular assist systems. (98) Recent studies show that Troponin T levels can predict persistent left ventricular dysfunction in peripartum cardiomyopathy (101) and found that baseline Fas/Apo-1 and higher NHYA at presentation were the only predictors of mortality. (96) MRI using late gadolinium enhancement may be useful for the evaluation of the extent of myocardial damage and to predict the outcome of PPCM.
(89)
Risk of recurrence in future pregnancies
The risk of developing PPCM in subsequent pregnancies remains high, (19) although the factors involved in the prognosis are still not fully understood and diversity in clinical features of PPCM causes diffi culties in making recommendations for future pregnancies.
The mechanism of recurrent symptomatic heart failure in patients with a history of PPCM and recovered left ventricular function has been attributed to a signifi cant physiological increase in blood volume, stroke volume and heart rate during pregnancy, (102) but the fi nding of marked depression of in left ventricular function with subsequent pregnancy suggests that worsening of symptoms are also due to reactivation of the underlying idiopathic process responsible for the development of cardiomyopathy in previous pregnancy. (103) While the outcome of subsequent pregnancies is better in women who have fully recovered heart function, (84) persistence of left ventricular dysfunction after 6 months indicates irreversible cardiomyopathy and portends worse prognosis. (18) Currently available data suggest that in patients with persistent left ventricular dysfunction strong recommendation to avoid additional pregnancies is warranted, while preconception counseling in patients with recovered left ventricular function is less consensual. (19, 92, 104) Research on neglected cardiomyopathies in Africa 
Neglected cardiomyopathies are currently a cause of major concern to African individuals, health managers, cardiologists and researchers. However, due to lack of human and material resources for research in most endemic areas, there is need for the creation of networks of local researchers that will be dedicated to investigate these diseases. This effort could be supported and coordinated by continental health professional organisations, with the involvement of African universities and non-governmental organisations dedicated to delivery of health care, professional training and cardiovascular research. Academic and sponsoring institutions in the developed world should be supportive of projects designed and lead by local investigators. (105) Particularly for EMF and PPCM most publications from Africa are several years old, based on small numbers of patients and/or using older criteria for diagnosis, which did not include echo-cardiography. We are of the opinion that the proposed risk factors associated with these cardiomyopathies requires serious reevaluation and that actual incidence could be estimated using modifi ed diagnostic criteria, particularly in endemic areas.
Herewith a description of two projects studying these entities in African countries: Mozambique and South Africa.
Endomyocardial fi brosis project (Mozambique)
The Heart Institute of Mozambique is a non-governmental organisation lead by local cardiologists, devoted to diagnosis, treatment and prevention of cardiovascular diseases, as well as research into African-specifi c forms of cardiovascular diseases.
It is a non-profi table institution that is established in Maputo city with the diagnosis of endomyocardial fi brosis are therefore being studied, of which 236 were detected during community studies.
In reaching out to the population in its environment the initial stages of the disease that were not previously described, can now be detected. (33) newly diagnosed cases, heart failure was the most common primary diagnosis (44% of cases) with most cases due to dilated cardio- 
